My Cart

Envelope protein

Envelope protein Overview

English NameRecombinant envelope proteinApproved Drugs1
Drugs in Clinical Trials6Target Synonymenv,Submitted name: Recombinant envelope protein,Viral Envelope Proteins
Highest Development StageApproved
English NameRecombinant envelope protein
Target Synonymenv,Submitted name: Recombinant envelope protein,Viral Envelope Proteins
Approved Drugs1
Drugs in Clinical Trials6
Highest Development StageApproved

Envelope protein Product List

  • Product Category

    Protein (2)Kits (1)

  • Product Status

    Launched (3)

  • Species

    SARS-CoV-2 (1)pHERV-W (1)- (1)

  • Tag

    His Tag & GST Tag (1)His Tag (1)- (1)

  • Conjugate

    Unconjugated (2)- (1)

Envelope protein Background

Dengue virus envelope (E) glycoprotein is a class II fusion protein mediating viral attachment and entry. Organized as dimers on the virion surface, it binds host receptors and, upon endosomal acidification, undergoes dramatic conformational rearrangements to drive membrane fusion. Structurally, E comprises three domains (DI, DII, DIII), with DIII responsible for receptor recognition. Highly immunogenic, E elicits neutralizing antibodies and is the principal target for vaccine design and therapeutic antibody development, as inhibiting its fusogenic transition blocks dengue virus infection.

Envelope protein Synonyms

Envelope protein,Env polyprotein,Envelope glycoprotein,env

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Targeting HIV-1 Env gp140 antibodiesPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
TemelimabGNN-001; GENHP-01; GNbAC-1Phase 2 ClinicalGeneuro SaDiabetes Mellitus, Type 1; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Post-Acute COVID-19 Syndrome
Details
VIS-513VIS-513; Ab-513Phase 2 ClinicalOtsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra IncDengue
Details
PGDM-1400PGDM-1400; PGDM1400LSPhase 2 ClinicalInternational Aids Vaccine InitiativeAcquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases, Viral
Details
MGD-020MGD020Phase 1 ClinicalMacrogenics IncHIV Infections
Details
GS-8588GS-8588Phase 1 ClinicalGilead Sciences IncHIV Infections
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
TecovirimatSIGA-246; ST-246ApprovedSiga Technologies IncTpoxx, ArestvyrUnited StatesSmallpoxSiga Technologies Inc2018-07-13Cowpox; Monkeypox; Orthopoxvirus Infection; Poxviridae Infections; Smallpox; Vaccinia
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland